[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Mizuho y'day🏁 $CLDX Outperform/$48 $NVS $REGN - SNY JSPR LLY TEVA ALLK Mizuho said: We are initiating coverage of Celldex Therapeutics with an Outperform rating and $XX PT as we see barzovolimab (anti-KIT mAb) as positioned to play a significant role in mast-cell mediated diseases namely chronic urticaria. We believe barzolvolimab has potential to establish best-in-class efficacy among the increasingly competitive landscape offering the deepest and most sustained clinical benefit. With this we performed probability modeling that we believe points to high probability of future statistical"
X Link @Quantumup1 2025-10-21T19:19Z 3863 followers, 1403 engagements